The study will be an open-label, Phase 1b study of R289 to determine tolerability and preliminary efficacy in patients with LR MDS who are relapsed, refractory/resistant, intolerant, or have inadequate response to prior therapies such as erythropoietin (EPO), thrombopoietin (TPO), luspatercept, or hypomethylating agents (HMAs) for MDS.
1 Primary · 2 Secondary · Reporting Duration: 2 Year
Experimental Treatment
22 Total Participants · 1 Treatment Group
Primary Treatment: Dose Escalation · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: